<p><h4>Evaluate the commercial prospects for:</h4>
<h1><span>Ganitumab</span></h1>
Company(ies): Amgen, Takeda
Principal Therapy Area: Cancer
Online, PDF
Ganitumab is a fully-human monoclonal antibody antagonist of insulin-like growth factor-1 (IGF-1) receptor, a protein important to the growth of tumours. Increased IGF-1 signalling mediates tumour proliferation, reduces apoptosis, and correlates with higher incidence and progression of common cancers. Ganitumab antibody binds to IGF-1 without cross-reacting with the closely-related insulin receptor.
Ganitumab exhibited broad antitumour activity in xenograft models, both as a monotherapy and when combined with chemotherapy.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Cost-effective collections
Customers focusing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link to direct_sales@espicom.com